2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
This guideline cites 4 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2021
- Source
- Glikson M, Nielsen JC, et al. Eur Heart J. 2021;42(35):3427–3520.doi 10.1093/eurheartj/ehab364
The 2021 ESC pacing guideline covers bradycardia pacing, cardiac resynchronisation therapy (CRT) and conduction-system pacing. The register's landmark CRT outcome trials that anchor its resynchronisation recommendations are listed below.
Cardiac resynchronisation therapy4
- 2010RAFTCardiology · Arrhythmia · CRTIn 1,798 patients with NYHA II-III heart failure, EF ≤ 30% and wide QRS, adding cardiac resynchronisation to an ICD reduced death or heart-failure hospitalisation compared with an ICD alone.HR 0.7595% CI 0.64-0.87Read →
- 2009MADIT-CRTCardiology · Arrhythmia · CRTIn 1,820 patients with mild heart failure (NYHA I–II) and a wide QRS, adding resynchronisation to a defibrillator reduced death or heart-failure events compared with a defibrillator alone.HR 0.66Read →
- 2005CARE-HF CoreCardiology · Arrhythmia · CRTIn 813 patients with heart failure and a wide QRS, cardiac resynchronisation therapy reduced death or unplanned cardiovascular hospitalisation compared with medical therapy.39% vs 55%Read →
- 2004COMPANIONCardiology · Arrhythmia · CRTIn 1,520 patients with NYHA III-IV heart failure and QRS ≥ 120 ms, cardiac resynchronisation therapy (with or without a defibrillator) reduced all-cause death or hospitalisation compared with optimal medical therapy alone.Read →
Cited landmark trials not yet in the register3
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.